Filing Details
- Accession Number:
- 0000899243-18-002535
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-01 19:07:24
- Reporting Period:
- 2018-01-30
- Accepted Time:
- 2018-02-01 19:07:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1707502 | Solid Biosciences Inc. | SLDB | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1578965 | Adam Koppel | C/O Bain Capital Life Sciences Investors Llc, 200 Clarendon Street Boston MA 02116 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-01-25 | 1,689,444 | $0.00 | 1,689,444 | No | 4 | M | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2018-01-30 | 300,000 | $16.00 | 1,989,444 | No | 4 | P | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | LLC Units | Acquisiton | 2017-10-26 | 1,223,240 | $0.00 | 1,037,919 | $0.00 |
| Common Stock | LLC Units | Disposition | 2018-01-25 | 1,991,097 | $0.00 | 1,689,444 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,991,097 | No | 4 | A | Indirect | ||
| 0 | No | 4 | M | Indirect |
Footnotes
- Represents shares held directly by BCLS SB Investco, LP ("BCLS").
- The governance, investment strategy and decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock.
- Represents shares purchased in the Issuer's initial public offering.
Billionaire Hedge Funds
